Quantum BioPharma Advances Lucid-MS Trial with Thermo Fisher Partnership

  • Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to implement its Phase 2 Lucid-MS trial for multiple sclerosis.
  • The trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in progressive forms of MS.
  • Thermo Fisher will support study start-up activities and related clinical research services.
  • Lucid-MS targets demyelination, a novel approach in MS treatment, aiming to address neurodegenerative processes.
  • The MS therapeutic market is projected to exceed $38 billion by 2030.

Quantum BioPharma's partnership with Thermo Fisher Scientific marks a critical step in advancing its Lucid-MS program, which targets demyelination in multiple sclerosis. This collaboration leverages Thermo Fisher's extensive experience in CNS and MS trials, positioning Lucid-MS to potentially address unmet patient needs in a market projected to exceed $38 billion by 2030. The strategic focus on neuroprotection differentiates Lucid-MS from existing therapies, highlighting Quantum BioPharma's innovative approach in the biopharmaceutical sector.

Trial Execution
How Quantum BioPharma will manage the operational challenges of initiating and conducting the Phase 2 trial with Thermo Fisher.
Regulatory Pathway
Whether the FDA clearance and subsequent trial results will pave the way for future approvals and commercialization of Lucid-MS.
Market Differentiation
The pace at which Lucid-MS can capture market share in the competitive MS therapeutics space, given its novel neuroprotective approach.